Executives at contract vaccine manufacturer Emergent BioSolutions covered up quality control problems that led to more than 400 million doses of coronavirus vaccines needing to be trashed, congressional investigators said in a report .... The FDA allowed Emergent to resume COVID-19 vaccine production in August 202 at the Baltimore plant. Emergent received $330 million in taxpayer funds before the federal government terminated the contract in November, the report said.Source: AP via MSN and U.S. House Committee on Oversight and Reform